| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01250639 |
| P698 | PubMed publication ID | 2563750 |
| P50 | author | Johannes Kornhuber | Q17068400 |
| Gavin P. Reynolds | Q43185490 | ||
| P2093 | author name string | P Riederer | |
| H Beckmann | |||
| K Jellinger | |||
| E Gabriel | |||
| P2860 | cites work | Diagnostic Criteria for Use in Psychiatric Research | Q34226390 |
| Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics | Q34559171 | ||
| The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs | Q34706538 | ||
| Multiple receptors for dopamine | Q37876912 | ||
| Change in the characteristics of 3H-spiperone binding to rat striatal membranes after acute chlorpromazine administration: Effects of buffer washing of membranes | Q39265191 | ||
| Normal prolactin responses in tardive dyskinesia | Q39298593 | ||
| Dopamine receptors and the dopamine hypothesis of schizophrenia | Q39471744 | ||
| Increased dopamine-receptor sensitivity in schizophrenia | Q39498162 | ||
| Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? | Q39897538 | ||
| Cerebrospinal Fluid Amine Metabolites in Acute Schizophrenia | Q41070554 | ||
| Imaging of neurotransmitter receptors in the living human brain | Q41348700 | ||
| Bimodal Distribution of Dopamine Receptor Densities in Brains of Schizophrenics | Q41536508 | ||
| Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia | Q41587309 | ||
| Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics | Q44239783 | ||
| Uptake of 77Br-spiperone in the striata of schizophrenic patients and controls | Q44863559 | ||
| Dopamine receptor subtype imbalance in schizophrenia | Q45078544 | ||
| Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases | Q45297058 | ||
| Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains | Q48166703 | ||
| A neuroendocrine study of supersensitivity in tardive dyskinesia | Q48259292 | ||
| Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum | Q48469734 | ||
| Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples | Q48648406 | ||
| Dopamine D2 receptors in substantia nigra in schizophrenia | Q48669886 | ||
| Characterization and regional distribution of serotonin S2-receptors in human brain | Q48724896 | ||
| Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? | Q48889468 | ||
| Increased brain dopamine and dopamine receptors in schizophrenia. | Q48903689 | ||
| Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum | Q48956377 | ||
| Dopamine receptors and schizophrenia: the neuroleptic drug problem | Q49153919 | ||
| [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. | Q51823312 | ||
| Central dopamine turnover in schizophrenic syndromes. | Q55061593 | ||
| Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin | Q60619470 | ||
| DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS | Q61714109 | ||
| Studies in postmortem dopamine uptake. II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia | Q68965633 | ||
| An experimental model of tardive dyskinesia | Q69454785 | ||
| No D2 receptor increase in PET study of schizophrenia | Q70033743 | ||
| Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration | Q70646262 | ||
| 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors | Q71564942 | ||
| Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment | Q72549857 | ||
| P433 | issue | 1 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 1-10 | |
| P577 | publication date | 1989-01-01 | |
| P1433 | published in | Journal of Neural Transmission | Q15750921 |
| P1476 | title | 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms | |
| P478 | volume | 75 |
| Q57781184 | (3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients |
| Q23922388 | 3H-spiperone labels sigma receptors, not dopamine D2 receptors, in rat and human lymphocytes |
| Q90427479 | A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter |
| Q97092488 | A focused update on tardive dyskinesia |
| Q48312237 | A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis |
| Q34383654 | Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia |
| Q36955877 | Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. |
| Q48532685 | Brain imaging of schizophrenia--the dopamine hypothesis |
| Q40473365 | Chemical brain anatomy in schizophrenia |
| Q41286489 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells |
| Q48854657 | Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes |
| Q48471657 | D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after |
| Q43942876 | Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study |
| Q38305872 | Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. |
| Q48404440 | Dopamine D2 densities and the schizophrenic brain. |
| Q40918315 | Dopamine in schizophrenia |
| Q61713976 | Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study |
| Q73528520 | Dysregulation of dopamine and pathology of prefrontal neurons: neuroimaging studies in schizophrenia and related animal models |
| Q38346296 | Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system |
| Q60513754 | Excitatory amino acids, NMDA and sigma receptors: A role in schizophrenia? |
| Q48326374 | Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia |
| Q34383604 | Hippocampal neurons in schizophrenia |
| Q42551036 | Hyperactive behavioural effects induced by intranigral infusion of a pyridinium metabolite of haloperidol in rats |
| Q33437467 | Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol |
| Q49068786 | In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia |
| Q48591328 | Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims |
| Q34703195 | Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials |
| Q46677709 | Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study |
| Q34540452 | Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution |
| Q36586088 | PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness |
| Q43564923 | Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex. |
| Q28346834 | Potassium chloride depolarization mediates CREB phosphorylation in striatal neurons in an NMDA receptor-dependent manner |
| Q48802317 | Presynaptic dopaminergic function in the striatum of schizophrenic patients |
| Q38399332 | Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus. |
| Q48777045 | Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness |
| Q33921370 | Schizophrenia: D4 receptor elevation. What does it mean? |
| Q37596400 | Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia |
| Q33627591 | Striatal dopamine D2 receptors in tardive dyskinesia: PET study |
| Q33396727 | Structural and functional brain imaging in schizophrenia |
| Q35071909 | Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials |
| Q63866035 | The limbic-striatal interaction: A seesaw rather than a tandem |
| Q41743479 | The neuroanatomy and neurochemistry of schizophrenia |
| Q56896418 | The neuropsychology of schizophrenia: A perspective from neurobehavioral genetics |
| Q73326319 | The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat |
| Q48247779 | The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. |
| Q36727004 | Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model |
| Q57403541 | Why don't preschizophrenic children have delusions and hallucinations? |
Search more.